NCT00967655Unknown2 期
A Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Radiation in Combination With Capecitabine & Paniumumab With and Without Irinotecan in Patients With Localized Rectal Cancer
Loma Linda Oncology Medical Group, Inc.8 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2009年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 54
- 试验地点
- 8
- 主要终点
- 1-year survival rate
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as capecitabine and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy, monoclonal antibody therapy, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying the side effects of giving capecitabine and panitumumab together with radiation therapy with or without irinotecan hydrochloride and to see how well it works in treating patients undergoing surgery for localized rectal cancer.
详细描述
OBJECTIVES:
Primary
- To assess the pathological tumor response rate in patients with localized rectal cancer treated with neoadjuvant chemoradiotherapy comprising capecitabine, panitumumab, and radiotherapy with or without irinotecan hydrochloride.
- To assess the incidence of grade 3/4 toxicity during neoadjuvant chemoradiotherapy.
Secondary
- To assess the disease-free survival.
- To assess the time to treatment failure.
- To assess the1-year and 2-year survival rates.
- To assess local recurrence, defined as recurrence in pelvis at the site of previous disease.
- To assess the safety and toxicity grade using NCI CTCAE v3.0 criteria.
- To assess the number and percentage of patients who undergo down staging of their disease as determined before initiating neoadjuvant therapy and at the time of surgery.
- To assess the number and percentage of patients where permanent colostomy can be avoided as determined by the surgeon before initiating neoadjuvant therapy and at the time actual surgery is performed.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed adenocarcinoma of the distal rectum (0-9 cm from the dentate line or 3-12 cm from the anal verge)
- •T3 or T4 tumor or nodal involvement by endorectal ultrasound or CT scan or MRI
- •Patients with any T status where tumor is close to but not involving the sphincter who otherwise would be candidates for abdominoperineal resection are eligible
- •No known homozygotes to UGT1A1* 28
- •No distant metastases
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-1
- •ANC ≥ 1,500/mm³
- •Platelet count ≥ 100,000/mm³
- •Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- •ALT and AST ≤ 3 times ULN
- •Serum creatinine ≤ 1.5 times ULN
- •Creatinine clearance ≥ 50 mL/min
- •Magnesium normal
- •Able to tolerate major surgery
- •Able and willing to comply with study requirements
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 4 weeks (males) or 24 weeks (females) after completion of study therapy
- •No prior diagnosis of interstitial lung disease
- •No prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to fluorouracil
- •No other prior or concurrent invasive malignancy unless disease-free for ≥ 5 years
- •No lack of physical integrity of the upper gastrointestinal tract, inability to swallow tablets, or malabsorption syndrome
- •No concurrent serious infections
- •No clinically significant cardiovascular disease within the past year, including any of the following:
- •Myocardial infarction
- •Unstable angina
- •Symptomatic congestive heart failure
- •Symptomatic coronary artery disease
- •Serious uncontrolled cardiac arrhythmia
- •No history of any medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase risks associated with study participation or investigational product(s) administration or may interfere with the interpretation of the study results
- •No known positivity for HIV, hepatitis C, or acute or chronic active hepatitis B
- •PRIOR CONCURRENT THERAPY:
- •No prior chemotherapy or radiotherapy for rectal cancer
- •No prior anti-EGFr antibody therapy (e.g., cetuximab)
- •No prior treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib hydrochloride, or lapatinib ditosylate)
- •No prior therapeutic radiotherapy to the pelvis
- •More than 28 days since prior major surgery
- •More than 14 days since prior minor surgery
- •At least 30 days since prior investigational agent or therapy
- •At least 4 weeks since prior and no concurrent sorivudine or brivudine
- •No concurrent chronic immunosuppressive agents (e.g., methotrexate or cyclosporine)
- •No concurrent cimetidine
排除标准
- 未提供
结局指标
主要结局
1-year survival rate
Grade 3/4 toxicity rate
Disease-free survival
Time to treatment failure
2-year survival rate
Pathological complete response rate
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
Unknown
1 期
Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00544063Institut du Cancer de Montpellier - Val d'Aurelle33
Unknown
1 期
Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With IrinotecanColorectal CancerNCT00496704Yonsei University56
已完成
2 期
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine TumorsGastrointestinal Carcinoid TumorIslet Cell TumorNCT00602082Cambridge University Hospitals NHS Foundation Trust84
已完成
1 期
Irinotecan and Capecitabine in Treating Women With Advanced Breast CancerBreast CancerNCT00083148Roswell Park Cancer Institute12
已完成
2 期
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by SurgeryMetastatic CancerColorectal CancerNCT00544349Gustave Roussy, Cancer Campus, Grand Paris45